Although iNOS is a key enzyme in the inflammatory and antiviral response, with its expression elevated during SARS-CoV-2 infection, existing genetic association studies and reviews have not reported any NOS1 and NOS2 variants (e.g., SNPs) as being significantly correlated with COVID-19 severity or outcomes. The gene discussed is NOS2; the disease is COVID-19.